Novel DNA intercalating anticancer drug curaxin CBL0137 significantly inhibited in vitro DNA methylation by eukaryotic DNA methyltransferase Dnmt3a catalytic domain View article: https://www.sciencedirect.com/science/article/abs/pii/S0960894X20304078
Thus, we propose a novel role for FACT as a factor preventing helicase dissociation from chromatin during replication stress. View article: https://www.nature.com/articles/s41388-020-1346-9
Two posters with the results of completed clinical trials that described CBL0137 safety, pharmacokinetics, and efficacy in patients with advanced solid tumors were presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting which was held on May 29-31, 2020 in the virtual format. Poster 337 (abstract #3607) described the results of the […]
The results of two completed clinical trials of the curaxin CBL0137 (oral and intravenous administration) in patients with advanced solid tumors will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2020 during the Poster Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology (posters #337 and #313). Join us on […]
The results of the research which describe the curaxin CBL0137 mechanism of action will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2020 by Professor Katerina Gurova from the Roswell Park Comprehensive Cancer Center. These studies were supported by Incuron. Join us on April 24-29, 2020, in San Diego, California.
Incuron will be presenting as a Top Innovator at the Life Sciences Track of The 2019 New England Venture Summit. Join us in Boston on December 4, 2019.